S
Stephen M. Taylor
Researcher at Government of Western Australia
Publications - 156
Citations - 8249
Stephen M. Taylor is an academic researcher from Government of Western Australia. The author has contributed to research in topics: C5a receptor & Receptor. The author has an hindex of 49, co-authored 155 publications receiving 7496 citations. Previous affiliations of Stephen M. Taylor include Heart of England NHS Foundation Trust & Department of Employment, Economic Development and Innovation.
Papers
More filters
Journal ArticleDOI
Pathophysiology, treatment, and animal and cellular models of human ischemic stroke
Trent M. Woodruff,John Thundyil,Sung-Chun Tang,Christopher G. Sobey,Stephen M. Taylor,Thiruma V. Arumugam +5 more
TL;DR: This review explores the etiology and pathogenesis of ischemic stroke, and provides a general model of such, and explores new and emerging approaches for the prevention and treatment of stroke.
Journal ArticleDOI
The role of the complement system in ischemia-reperfusion injury.
TL;DR: The use of specific inhibitors to block complement activation has been shown to prevent local tissue injury after I/R, and novel inhibitors of complement products may find wide clinical application because there are no effective drug therapies currently available to treat I-R injuries.
Journal ArticleDOI
Toll-like receptors in ischemia-reperfusion injury.
Thiruma V. Arumugam,Eitan Okun,Sung-Chun Tang,John Thundyil,Stephen M. Taylor,Trent M. Woodruff +5 more
TL;DR: The contribution of TLR activation in hepatic, renal, cerebral, intestinal, and myocardial I/R injuries is discussed and the development of specific TLR-targeted therapeutics to treat these conditions is discussed.
Journal ArticleDOI
Low-Molecular-Weight Peptidic and Cyclic Antagonists of the Receptor for the Complement Factor C5a
Angela M. Finch,A. K. Wong,Natalii J Paczkowski,S. K. Wadi,David J. Craik,David P. Fairlie,Stephen M. Taylor +6 more
TL;DR: A series of small molecules derived from the C-terminus of C5a are described, some of which are the most potent low-molecular-weight C 5a receptor antagonists reported to date for the human polymorphonuclear leukocyte (PMN) C5A receptor.
Journal ArticleDOI
Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease.
Maria I. Fonseca,Rahasson R. Ager,Shu Hui Chu,Ozkan Yazan,Sam D. Sanderson,Frank M. LaFerla,Stephen M. Taylor,Trent M. Woodruff,Andrea J. Tenner +8 more
TL;DR: Oral delivery of a cyclic hexapeptide C5a receptor antagonist for 2–3 mo resulted in substantial reduction of pathological markers such as fibrillar amyloid deposits and activated glia in two mouse models of AD, suggesting a novel therapeutic target for reducing pathology and improving cognitive function in human AD patients.